ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly

计划入组 8 人 · 首次发布于 2025 年 6 月 25 日

An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy

计划入组 1,180 人 · 首次发布于 2026 年 8 月 28 日

Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

计划入组 1,181 人 · 首次发布于 2023 年 12 月 28 日

ALXN2080

Paltusotine Poised for Major Market Impact as First Oral Acromegaly Therapy Gains FDA Approval

FDA Grants Fast Track Designation to ALXN2220 for ATTR Amyloidosis with Cardiomyopathy